X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (15) 15
index medicus (15) 15
male (12) 12
aged (11) 11
female (11) 11
middle aged (10) 10
hematology (9) 9
oncology (8) 8
adult (6) 6
antineoplastic combined chemotherapy protocols - therapeutic use (6) 6
chemotherapy (6) 6
disease-free survival (6) 6
follow-up studies (6) 6
prognosis (6) 6
rituximab (6) 6
treatment outcome (6) 6
antineoplastic combined chemotherapy protocols - administration & dosage (5) 5
antineoplastic combined chemotherapy protocols - adverse effects (5) 5
doxorubicin (5) 5
antibodies, monoclonal - administration & dosage (4) 4
care and treatment (4) 4
lymphomas (4) 4
non-hodgkins-lymphoma (4) 4
prospective studies (4) 4
survival (4) 4
abridged index medicus (3) 3
alzheimer's disease (3) 3
antibodies, monoclonal, murine-derived (3) 3
cohort studies (3) 3
cyclophosphamide - administration & dosage (3) 3
cytarabine (3) 3
disease (3) 3
dosage and administration (3) 3
dose-response relationship, drug (3) 3
doxorubicin - administration & dosage (3) 3
drug administration schedule (3) 3
drug therapy (3) 3
drug therapy, combination (3) 3
health aspects (3) 3
hematology, oncology and palliative medicine (3) 3
medicine & public health (3) 3
non-hodgkin's lymphomas (3) 3
patients (3) 3
prednisone - administration & dosage (3) 3
recurrence (3) 3
usage (3) 3
vincristine - administration & dosage (3) 3
aged, 80 and over (2) 2
animals (2) 2
antibodies, monoclonal, murine-derived - administration & dosage (2) 2
antineoplastic agents - administration & dosage (2) 2
antineoplastic agents - adverse effects (2) 2
caenorhabditis elegans (2) 2
cancer (2) 2
cardiotoxicity (2) 2
clinical trials (2) 2
combined modality therapy (2) 2
computed tomography (2) 2
cyclophosphamide (2) 2
cyclophosphamide - adverse effects (2) 2
cytarabine - administration & dosage (2) 2
cytarabine - adverse effects (2) 2
cytarabine - therapeutic use (2) 2
diagnosis (2) 2
disease progression (2) 2
doxorubicin - adverse effects (2) 2
drug dosages (2) 2
follow-up (2) 2
granulocyte colony-stimulating factor - administration & dosage (2) 2
hodgkin disease - diagnostic imaging (2) 2
hodgkin disease - drug therapy (2) 2
immunochemotherapy (2) 2
incidence (2) 2
internal medicine (2) 2
italy (2) 2
italy - epidemiology (2) 2
kaplan-meier estimate (2) 2
lenograstim (2) 2
lymphoma, b-cell - drug therapy (2) 2
lymphoma, b-cell - mortality (2) 2
lymphoma, large b-cell, diffuse - drug therapy (2) 2
lymphoma, non-hodgkin - drug therapy (2) 2
lymphoma, non-hodgkin - mortality (2) 2
monoclonal antibodies (2) 2
multivariate analysis (2) 2
neutropenia (2) 2
olive oil (2) 2
original article (2) 2
paralysis (2) 2
positron-emission-tomography (2) 2
prednisone - adverse effects (2) 2
pyrans - pharmacology (2) 2
radiotherapy (2) 2
retrospective studies (2) 2
risk factors (2) 2
therapy (2) 2
trial (2) 2
vincristine - adverse effects (2) 2
young adult (2) 2
1st-line treatment (1) 1
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet, The, ISSN 0140-6736, 2009, Volume 374, Issue 9700, pp. 1512 - 1520
Summary Background Chemotherapy with high-dose methotrexate is the conventional approach to treat primary CNS lymphomas, but superiority of polychemotherapy... 
Internal Medicine | DEFERRED RADIOTHERAPY | MEDICINE, GENERAL & INTERNAL | B-CELL LYMPHOMA | INTERNATIONAL WORKSHOP | RESPONSE CRITERIA | EUROPEAN ORGANIZATION | CONSOLIDATING RADIOTHERAPY | NON-HODGKINS-LYMPHOMA | INITIAL TREATMENT | CENTRAL-NERVOUS-SYSTEM | CEREBROSPINAL-FLUID | Follow-Up Studies | Cytarabine - therapeutic use | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Cytarabine - adverse effects | Methotrexate - therapeutic use | Lymphoma, Non-Hodgkin - radiotherapy | Cranial Irradiation - methods | Central Nervous System Neoplasms - radiotherapy | Adult | Lymphoma, Non-Hodgkin - drug therapy | Drug Administration Schedule | Kaplan-Meier Estimate | Proportional Hazards Models | Logistic Models | Treatment Outcome | Combined Modality Therapy | Remission Induction | Methotrexate - adverse effects | Antimetabolites, Antineoplastic - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Antimetabolites, Antineoplastic - adverse effects | Aged | Lymphoma, Non-Hodgkin - mortality | Central Nervous System Neoplasms - drug therapy | Central Nervous System Neoplasms - mortality | Cytarabine | Patient outcomes | Central nervous system diseases | Dosage and administration | Lymphomas | Drug therapy, Combination | Methotrexate | Drug therapy | Data analysis | Disease | Monoclonal antibodies | Data collection | Radiation therapy | Patients | Tropical diseases | Index Medicus | Abridged Index Medicus
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2008, Volume 9, Issue 4, pp. 352 - 358
Journal Article
Lancet Haematology, The, ISSN 2352-3026, 2016, Volume 4, Issue 1, pp. e15 - e23
Journal Article
Lancet Haematology, The, ISSN 2352-3026, 2016, Volume 3, Issue 10, pp. e467 - e479
Journal Article
Hematological Oncology, ISSN 0278-0232, 03/2017, Volume 35, Issue 1, pp. 69 - 78
Journal Article
Supportive Care in Cancer, ISSN 0941-4355, 9/2014, Volume 22, Issue 9, pp. 2557 - 2561
The risk of febrile neutropenia (FN) in cancer patients receiving chemotherapy is mainly due to the type of chemotherapy regimen and the presence of specific... 
Lenograstim | Pain Medicine | Nadir | Pegfilgrastim | Nursing | Rehabilitation Medicine | NHL | Medicine & Public Health | Oncology | G-CSF | Nursing Management/Nursing Research | Neutropenia | MULTICENTER | SINGLE-ADMINISTRATION PEGFILGRASTIM | GUIDELINES | INDUCED FEBRILE NEUTROPENIA | MYELOID TOXICITY | OPPORTUNITIES | RECEIVING ADJUVANT CHEMOTHERAPY | CANCER-PATIENTS | ONCOLOGY | HEALTH CARE SCIENCES & SERVICES | REHABILITATION | DAILY FILGRASTIM | SCHEDULES | Thrombocytopenia - epidemiology | Cyclophosphamide - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Prospective Studies | Humans | Middle Aged | Antibodies, Monoclonal, Murine-Derived - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Recombinant Proteins - adverse effects | Cyclophosphamide - adverse effects | Feasibility Studies | Incidence | Dose-Response Relationship, Drug | Young Adult | Vincristine - administration & dosage | Adult | Female | Doxorubicin - administration & dosage | Lymphoma, Non-Hodgkin - drug therapy | Granulocyte Colony-Stimulating Factor - adverse effects | Prednisone - administration & dosage | Prednisone - adverse effects | Drug Administration Schedule | Risk Factors | Thrombocytopenia - chemically induced | Lymphoma, Non-Hodgkin - epidemiology | Recombinant Proteins - administration & dosage | Vincristine - adverse effects | Aged | Antibodies, Monoclonal, Murine-Derived - adverse effects | Doxorubicin - adverse effects | Granulocyte Colony-Stimulating Factor - administration & dosage | Care and treatment | Chemotherapy | Non-Hodgkin's lymphomas | Macrophage colony stimulating factor | Cancer | Side effects | Lymphomas | Drug dosages | Risk factors | Index Medicus | Original
Journal Article
Journal Article
Journal Article
Journal of blood medicine, ISSN 1179-2736, 2019, Volume 10, pp. 21 - 27
We conducted a retrospective study to evaluate the efficacy and related costs of using two different molecules of granulocyte-colony stimulating factor (G-CSF)... 
Biological products | Transplants & implants | Hematology | Neutrophils | Breast cancer | Hospitalization | Patients | Cancer therapies | Chemotherapy | Hospitals | Granulocytes | Stem cells | Lymphomas | Drug dosages | Neutropenia | filgrastim | Lenograstim | neutropenia | cost | biosimilar
Journal Article
Journal Article